Platinum versus non-platinum chemotherapy regimens for small cell lung cancer

Amarasena, I; Walters, Julia; Wood‐Baker, Richard; Fong, Kwun M.

doi:10.1002/14651858.cd006849.pub2

Cited by 38 publications

(29 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…2 As a result, systemic chemotherapy continues to be the mainstay of treatment to improve the survival and quality of life of patients. 3 In the last years, newer drugs that specifically target molecular pathways in NSCLC have been FDA approved showing promising results for the treatment of lung cancer. 4 Despite recent advances, response rates in NSCLC remain <50% and the 5-year survival rate for stage IV disease is about 1%.…”

Section: Introductionmentioning

confidence: 99%

Enhanced Anticancer Activity of PF-04691502, a Dual PI3K/mTOR Inhibitor, in Combination With VEGF siRNA Against Non–small-cell Lung Cancer

España-Serrano

Chougule

2016

Molecular Therapy - Nucleic Acids

View full text Add to dashboard Cite

Lung cancer is the leading cause of cancer deaths in both men and women in the United States accounting for about 27% of all cancer deceases. In our effort to develop newer therapy for lung cancer, we evaluated the combinatory antitumor effect of siRNA targeting VEGF and the PI3K/mTOR dual inhibitor PF-04691502. We analyzed the anticancer effect of siRNA VEGF and PF-04691502 combination on proliferation, colony formation and migration of A549 and H460 lung cancer cells. Additionally, we assessed the combination treatment antiangiogenic effect on human umbilical vein endothelial cells. Here, we show for the first time that the antiangiogenic siRNA VEGF potentiates the PF-04691502 anticancer activity against non–small-cell lung cancer. We observed a significant (P < 0.05) decrease in cell viability, colony formation, and migration for the combination comparing with the single drug treatment. We also showed a significant (P < 0.05) enhanced effect of the combination treatment inhibiting angiogenesis progression and tube formation organization compared to the single drug treatment groups. Our findings demonstrated an enhanced synergistic anticancer effect of siRNA VEGF and PF-04691502 combination therapy by targeting two main pathways involved in lung cancer cell survival and angiogenesis which will be useful for future preclinical studies and potentially for lung cancer patient management.

show abstract

Section: Introductionmentioning

confidence: 99%

Enhanced Anticancer Activity of PF-04691502, a Dual PI3K/mTOR Inhibitor, in Combination With VEGF siRNA Against Non–small-cell Lung Cancer

España-Serrano

Chougule

2016

Molecular Therapy - Nucleic Acids

View full text Add to dashboard Cite

show abstract

“…The estimated incidence of anemia in lung cancer patients undergoing chemotherapy ranges from 50% to 86%, increasing over the course of treatment [1,4,5] and occurring commonly in patients receiving platinum-based regimens [6]. Treatments for anemia associated with myelosuppressive chemotherapy include red blood cell (RBC) transfusions and erythropoiesis-stimulating agents (ESAs).…”

Section: Introductionmentioning

confidence: 99%

Benefits and risks of using erythropoiesis-stimulating agents (ESAs) in lung cancer patients: Study-level and patient-level meta-analyses

Vansteenkiste¹,

Glaspy

Henry

et al. 2012

Lung Cancer

View full text Add to dashboard Cite

In anemic patients receiving myelosuppressive chemotherapy, erythropoiesis-stimulating agents (ESAs) raise hemoglobin levels and reduce transfusion requirements, but ESA-related safety concerns exist. To evaluate ESA benefits and risks in lung cancer, we conducted meta-analyses of data from controlled ESA trials conducted in lung cancer patients. Study-level analyses included controlled ESA trials reporting lung cancer mortality, identified from the 2006 Cochrane ESA report and from a systematic search for studies published through December 2010. Patient-level analyses included data from lung cancer patients receiving chemotherapy in Amgen studies evaluating darbepoetin alfa (DA) vs placebo. Study-level and patient-level analyses examined deaths, progression, and transfusion incidence. Patient-level analyses also examined adverse events (AEs) and fatigue. In a study-level meta-analysis of nine ESA studies of 2342 patients receiving chemotherapy, the ESA odds ratio (OR) was 0.87 (95% confidence interval [CI] 0.69-1.09) for mortality; the overall random-effects risk difference (95% CI) for mortality was -0.02 (-0.06, 0.02). The ESA OR (95% CI) for disease progression in five chemotherapy studies reporting progression was 0.84 (0.65-1.09). The ESA odds ratio (95% CI) was 0.34 (0.28-0.41) for transfusion incidence. In a patient-level meta-analysis of four studies evaluating 1009 patients through follow-up, the median survival time was 41 weeks with DA and 38 weeks with placebo. During the combined study and follow-up periods, 80% of placebo-group patients and 74% of DA patients died (mortality hazard ratio [HR] 0.90 [95% CI, 0.78-1.03] for DA); results were similar for small cell lung cancer and non-small cell lung cancer. Overall, 87% of placebo patients and 84% of DA patients progressed or died. Fewer DA patients had transfusions (week 5 through end-of-study, DA 19%, placebo 43%). AEs included thrombotic/embolic events (DA 10.5%, placebo 7.2%), cerebrovascular disorders (DA 3.7%, placebo 4.2%), pulmonary edema (DA 0.4%, placebo 1.0%) and pulmonary embolism (DA 1.8%, placebo 0.6%). These meta-analyses suggest that ESAs reduce transfusions without increasing mortality or disease progression in lung cancer patients undergoing chemotherapy.

show abstract

“…3 Platinum therapy is considered one of the most efficacious agents. 4 Etoposide and cisplatin (EP) used in combination is the most common treatment regimen for extensive-stage SCLC. This regimen, which has been the mainstay of treatment for patients with extensive-stage SCLC since the 1980s, 5 is less toxic and more effective than single-agent treatment with oral etoposide.…”

Section: Introductionmentioning

confidence: 99%

Cisplatin plus etoposide versus other platin‐based regimens for patients with extensive small‐cell lung cancer: a systematic review and meta‐analysis of randomised, controlled trials

Jiang

Yang

Guan

et al. 2012

Internal Medicine Journal

View full text Add to dashboard Cite

show abstract

Platinum versus non-platinum chemotherapy regimens for small cell lung cancer

Cited by 38 publications

References 47 publications

Enhanced Anticancer Activity of PF-04691502, a Dual PI3K/mTOR Inhibitor, in Combination With VEGF siRNA Against Non–small-cell Lung Cancer

Enhanced Anticancer Activity of PF-04691502, a Dual PI3K/mTOR Inhibitor, in Combination With VEGF siRNA Against Non–small-cell Lung Cancer

Benefits and risks of using erythropoiesis-stimulating agents (ESAs) in lung cancer patients: Study-level and patient-level meta-analyses

Cisplatin plus etoposide versus other platin‐based regimens for patients with extensive small‐cell lung cancer: a systematic review and meta‐analysis of randomised, controlled trials

Contact Info

Product

Resources

About